TABLE 1.
Medicare Use and Spending on Prescription Drugs Facing Price Negotiations (2020)
| Drug name (Brand) | Total Part D claims (millions)a | Total Part D spending (billions) a,b | Part D mean (median) spending per claimb | Part D mean (median) total spending per beneficiary per drugb | Unique beneficiariesa |
|---|---|---|---|---|---|
| Apixaban (Eliquis) | 15,048,580 | $10,078,119,040 | $670 (489) | $4,135 (4,622) | 2,518,740 |
| Rivaroxaban (Xarelto) | 6,575,295 | $4,771,942,720 | $726 (494) | $4,498 (5,089) | 1,125,465 |
| Sitagliptin phosphate (Januvia) | 4,716,425 | $3,922,768,640 | $832 (500) | $4,462 (4,997) | 825,230 |
| Insulin aspart (Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill) | 3,695,410 | $3,035,492,480 | $821 (579) | $4,684 (3,522) | 729,920 |
| Ibrutinib (Imbruvica) | 231,090 | $2,948,750,400 | $12,760 (13,031) | $126,205 (145,952) | 24,850 |
| Empagliflozin (Jardiance) | 2,717,050 | $2,415,311,680 | $889 (549) | $4,465 (4,811) | 497,340 |
| Etanercept (Enbrel) | 342,175 | $2,219,628,000 | $6,487 (5,749) | $53,876 (58,412) | 42,310 |
| Sacubitril and valsartan (Entresto) | 1,524,510 | $1,223,642,000 | $803 (573) | $4,712 (5,089) | 222,355 |
| Ustekinumab (Stelara) | 55,165 | $1,126,836,880 | $20,427 (23,079) | $114,602 (95,226) | 11,995 |
| Dapagliflozin (Farxiga) | 863,265 | $743,649,200 | $861 (536) | $4,339 (4,739) | 151,860 |
| All 10 drugs | 35,768,965 | $32,486,141,040 | $908 (500) | $6,459 (5,059) | 6,150,065 |
| Nonnegotiated drugs | 1,488,526,080 | $169,453,742,080 | $114 (13) | $3,538 (620) | 47,340,190 |
a Number of claims, total spending, and number of unique beneficiaries are inflated by a multiple of 5 since data were 20% restricted sample.
b Part D spending includes Medicare spending, patient OOP spending, and third-party spending.